RxDoctor Payments Data

Diana Smith, NP

Psychiatric/Mental Health · Pueblo, CONPI 1689948424

Payments from drug & device makers

$3,073in general payments, 2019–2025

Across 105 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$626
  • Neurocrine Biosciences, Inc.$468
  • Lundbeck LLC$378
  • Teva Pharmaceuticals USA, Inc.$372
  • AbbVie$324
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$271
  • plus $634 from 7 others

What the payments were for

  • Food & beverage$3,02498%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,073 in reported general payments places this provider in the 90th percentile of 873 psychiatric/mental health providers in Colorado.

See all psychiatric/mental health providers in Colorado

Medicare billing

Part B allowed, 2024
$13,839
Medicare patients
26
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole74$122,930
VraylarCariprazine Hcl29$48,170
TrintellixVortioxetine Hydrobromide30$28,385
BelsomraSuvorexant15$14,948
Quetiapine Fumarate74$1,964
Buspirone Hcl86$1,712
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,376
Hydroxyzine Hcl74$1,351
Divalproex Sodium16$1,067
Aripiprazole55$988
Duloxetine Hcl33$981
Gabapentin69$823
Clonazepam42$724
Hydroxyzine Pamoate37$689
Trazodone Hcl61$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$31$122,93074 claims
AbbVieVraylar$324$48,17029 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$100$28,38530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 873 psychiatric/mental health providers in Colorado.

Other psychiatric/mental health in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →